EP3151822A4 - Combinaison à dose fixe utilisable en vue du traitement de la douleur et n'induisant pas d'oedème - Google Patents

Combinaison à dose fixe utilisable en vue du traitement de la douleur et n'induisant pas d'oedème Download PDF

Info

Publication number
EP3151822A4
EP3151822A4 EP15806490.7A EP15806490A EP3151822A4 EP 3151822 A4 EP3151822 A4 EP 3151822A4 EP 15806490 A EP15806490 A EP 15806490A EP 3151822 A4 EP3151822 A4 EP 3151822A4
Authority
EP
European Patent Office
Prior art keywords
edema
pain relief
fixed dose
dose combination
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15806490.7A
Other languages
German (de)
English (en)
Other versions
EP3151822A1 (fr
Inventor
Vuong Trieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autotelic LLC
Original Assignee
Autotelic LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/011148 external-priority patent/WO2016114761A1/fr
Application filed by Autotelic LLC filed Critical Autotelic LLC
Publication of EP3151822A1 publication Critical patent/EP3151822A1/fr
Publication of EP3151822A4 publication Critical patent/EP3151822A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP15806490.7A 2014-06-08 2015-06-08 Combinaison à dose fixe utilisable en vue du traitement de la douleur et n'induisant pas d'oedème Withdrawn EP3151822A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462009300P 2014-06-08 2014-06-08
US201462023962P 2014-07-14 2014-07-14
PCT/US2015/011148 WO2016114761A1 (fr) 2015-01-13 2015-01-13 Méthode pour pharmacothérapie individualisée
PCT/US2015/034706 WO2015191460A1 (fr) 2014-06-08 2015-06-08 Combinaison à dose fixe utilisable en vue du traitement de la douleur et n'induisant pas d'œdème

Publications (2)

Publication Number Publication Date
EP3151822A1 EP3151822A1 (fr) 2017-04-12
EP3151822A4 true EP3151822A4 (fr) 2017-11-22

Family

ID=54834151

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15806490.7A Withdrawn EP3151822A4 (fr) 2014-06-08 2015-06-08 Combinaison à dose fixe utilisable en vue du traitement de la douleur et n'induisant pas d'oedème
EP15807276.9A Withdrawn EP3151823A4 (fr) 2014-06-08 2015-06-08 Combinaison à dose fixe utilisable en vue du soulagement de la douleur et n'induisant pas d' dème

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15807276.9A Withdrawn EP3151823A4 (fr) 2014-06-08 2015-06-08 Combinaison à dose fixe utilisable en vue du soulagement de la douleur et n'induisant pas d' dème

Country Status (8)

Country Link
EP (2) EP3151822A4 (fr)
JP (2) JP2017517529A (fr)
KR (2) KR20160091348A (fr)
CN (2) CN106572985A (fr)
AU (2) AU2015274908A1 (fr)
CA (2) CA2956897A1 (fr)
TW (2) TW201642906A (fr)
WO (2) WO2015191473A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115057A1 (fr) * 2015-01-13 2016-07-21 Autotelic Llc Association médicamenteuse à dose fixe destinée au soulagement de la douleur sans induire d'œdème
US20200306211A1 (en) * 2015-11-30 2020-10-01 Pharnext Method for adapting doses of combination therapies
CA3160278A1 (fr) * 2019-12-04 2021-06-10 Balasingam Radhakrishnan Procedes et compositions pour traiter un oedeme refractaire a des diuretiques oraux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058073A2 (fr) * 2004-11-23 2006-06-01 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques renfermant un inhibiteur selectif de la cox-2 et un diuretique
WO2009154944A2 (fr) * 2008-05-28 2009-12-23 Hoyle Peter C Formulations pharmaceutiques et procédés d'utilisation combinant des composés antiinflammatoires non stéroïdes et des composés anti-hypertensifs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005799A2 (fr) * 2000-07-13 2002-01-24 Pharmacia Corporation Composes vasomodulateurs et inhibiteurs selectifs de la cyclo-oxygenase-2 pour le traitement des douleurs generalisees et des cephalees
US20090215852A1 (en) * 2005-03-21 2009-08-27 Chroma Group, Inc. Compositions and methods for ameliorating cachexia
EP2014284A1 (fr) * 2007-06-15 2009-01-14 Novartis AG Compositions pharmaceutiques et utilisations
JP6184943B2 (ja) * 2011-05-30 2017-08-23 オートテリック エルエルシー ポイント・オブ・ケア薬物動態プロフィールによる治療薬モニタリングおよび用量投与のための方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058073A2 (fr) * 2004-11-23 2006-06-01 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques renfermant un inhibiteur selectif de la cox-2 et un diuretique
WO2009154944A2 (fr) * 2008-05-28 2009-12-23 Hoyle Peter C Formulations pharmaceutiques et procédés d'utilisation combinant des composés antiinflammatoires non stéroïdes et des composés anti-hypertensifs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOORE R ANDREW ET AL: "Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 3, 24 March 2005 (2005-03-24), pages R644 - R665, XP021011594, ISSN: 1465-9905, DOI: 10.1186/AR1704 *
SANJIVE QAZI ET AL: "Abstract 2597: Celecoxib fixed dose combinations - patient level data analyses", CANCER RESEARCH, vol. 77, no. 13 Supplement, 1 July 2017 (2017-07-01), US, pages 2597 - 2597, XP055416583, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2017-2597 *
See also references of WO2015191460A1 *
W WANG ET AL: "Poster Number 110: Patient-level Data Analysis Revealed the Real Incidence and Impact of Celecoxib on Edema", CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, vol. 6, no. Suppl 1, 1 September 2017 (2017-09-01), pages 69 - 70, XP055416585, DOI: 10.1002/cpdd.385 *

Also Published As

Publication number Publication date
EP3151823A4 (fr) 2017-11-22
EP3151823A1 (fr) 2017-04-12
JP2017517529A (ja) 2017-06-29
JP2017517575A (ja) 2017-06-29
TW201642854A (en) 2016-12-16
TW201642906A (en) 2016-12-16
CN106572985A (zh) 2017-04-19
CA2956899A1 (fr) 2015-12-17
WO2015191460A1 (fr) 2015-12-17
CA2956897A1 (fr) 2015-12-17
WO2015191473A1 (fr) 2015-12-17
AU2015274895A1 (en) 2017-02-02
AU2015274908A1 (en) 2017-01-19
WO2015191473A9 (fr) 2016-03-24
KR20160091348A (ko) 2016-08-02
CN106572984A (zh) 2017-04-19
KR20160091349A (ko) 2016-08-02
EP3151822A1 (fr) 2017-04-12

Similar Documents

Publication Publication Date Title
EP3463464A4 (fr) Traitement d'association
EP3332717A4 (fr) Dispositif de traitement
EP3199628A4 (fr) Agent thérapeutique induisant une cytotoxicité
EP3104807B8 (fr) Dispositif de traitement dentaire
EP3180010A4 (fr) Polythérapie pour le traitement du cancer
EP3169325A4 (fr) Composés inhibiteurs thérapeutiques
EP3445750A4 (fr) Composés thérapeutiques
EP3193884A4 (fr) Polythérapie pour le traitement du cancer
EP3184093A4 (fr) Dispositif de massage
GB201415569D0 (en) Therapeutic Compounds
EP3229974A4 (fr) Applicateur antiseptique
EP3020430A4 (fr) Canule pour thérapie d'intégration de catgut
EP3188721A4 (fr) Agents thérapeutiques humains
EP3515414A4 (fr) Polythérapie
EP3097880A4 (fr) Appareil thérapeutique
EP3512553A4 (fr) Thérapie par épuisement de klrg1
EP3419959A4 (fr) Traitement combiné
EP3362091A4 (fr) Polythérapie
EP3157631A4 (fr) Traitement des maladies neurodégénératives
EP3271014A4 (fr) Dispositif de photothérapie
EP3302394A4 (fr) Dispositifs de stimulation sexuelle
EP3259254A4 (fr) Composés thérapeutiques
EP3171876A4 (fr) Polythérapie
EP3131619A4 (fr) Dispositifs de stimulation
EP3148556A4 (fr) Préparations de traitement de la peau

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20171025

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/549 20060101ALI20171019BHEP

Ipc: A61K 45/06 20060101ALI20171019BHEP

Ipc: A61P 7/10 20060101ALI20171019BHEP

Ipc: A61K 9/00 20060101AFI20171019BHEP

Ipc: A61K 31/635 20060101ALI20171019BHEP

Ipc: A61P 25/00 20060101ALI20171019BHEP

Ipc: A61P 29/00 20060101ALI20171019BHEP

Ipc: A61K 31/415 20060101ALI20171019BHEP

Ipc: A61P 43/00 20060101ALI20171019BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180523